Loading...
XNYS
AVTR
Market cap7.18bUSD
Jul 09, Last price  
10.51USD
1D
7.68%
1Q
33.04%
IPO
-31.80%
Name

Avantor Inc

Chart & Performance

D1W1MN
XNYS:AVTR chart
P/E
P/S
1.10
EPS
Div Yield, %
Shrs. gr., 5y
3.09%
Rev. gr., 5y
0.49%
Revenues
6.55b
-3.41%
4,909,600,000636,900,000691,300,0001,247,400,0005,864,300,0006,040,300,0006,393,600,0007,386,100,0007,512,400,0006,967,200,0006,783,600,0006,552,200,000
Net income
-530m
L
686,500,00021,600,000-42,400,000-112,700,000-86,900,00037,800,000116,600,000572,600,000686,500,000321,100,000711,500,000-530,200,000
CFO
624m
-25.81%
843,600,000124,600,00072,900,000-167,500,000200,500,000354,000,000929,800,000953,600,000843,600,000870,000,000840,800,000623,800,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Avantor, Inc., a company established in 1904 and based in Radnor, Pennsylvania, is a global provider of vital products and specialized services. Operating across the Americas, Europe, Asia, the Middle East, and Africa, Avantor caters to a wide array of industries, including biopharmaceuticals, healthcare, educational institutions, government bodies, advanced technology firms, and applied materials enterprises. The company's extensive product portfolio features essential materials and consumables, such as high-purity chemicals and reagents, laboratory supplies, custom-formulated silicone materials, tailored excipients, single-use assemblies, process chromatography resins and columns, analytical sample preparation kits, educational and microbiology products, clinical trial kits, peristaltic pumps, and various fluid handling tips. Beyond consumables, Avantor also supplies advanced equipment and instrumentation. This range includes filtration and virus inactivation systems, incubators, analytical devices, evaporators, ultra-low-temperature freezers, biological safety cabinets, and critical environment supplies. Complementing its product offerings, Avantor delivers a suite of crucial services. These encompass on-site laboratory and production support, clinical services, equipment maintenance, comprehensive procurement and sourcing solutions, and specialized biopharmaceutical material scale-up and development expertise.
IPO date
May 17, 2019
Employees
14,500
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT